Latest News & Features
Americas
Amarin delayed the market entry of generic versions of the cardiovascular drug Vascepa by using supply agreements to halt competitors from accessing the drug’s active pharmaceutical ingredient, according to a new antitrust lawsuit. 29 April 2021
Generics
Mylan can deduct legal fees from defending itself against patent infringement suits as business expenses, according to the US Tax Court. 29 April 2021
article
As patent protections expire, drug repositioning has become a matter of intense interest. Aris Persidis founded Biovista in 2005 and has focused on using artificial intelligence to match drugs against any and all mechanisms, pathways, diseases and clinical outcomes. 29 April 2021
Big Pharma
Ghana’s pharmaceutical industry has asked AstraZeneca about acquiring rights to produce its COVID vaccine locally, buoying the country’s inoculation efforts. 27 April 2021
Generics
The UK High Court has refused to invalidate an Alcon glaucoma treatment patent in a judgment handed down on Friday, April 23. 27 April 2021
Big Pharma
Pfizer has discovered counterfeit versions of its COVID-19 vaccine in Mexico and Poland, prompting governments to reassure the public over the safety of vaccine supply chains. 27 April 2021
Big Pharma
The US Supreme Court heard oral arguments in Minerva Surgical v Hologic yesterday to discuss the potential abandoning of assignor estoppel. 22 April 2021
Americas
In a boon for eye care specialist Nicox, the United States Patent and Trademark Office has confirmed that one of its three patents covering a glaucoma treatment could be extended by up to five years. 22 April 2021
article
Now the race for the vaccine has been won, and we have 3 working vaccines. The next major battle against Covid-19 is the successful distribution of them. Major pharmaceutical companies came together collaboratively to win the first battle, so why is the second proving so hard? 22 April 2021
Americas
L’Oreal has secured a victory after a US federal court ruled that the French cosmetics brand did not infringe patents owned by the University of Massachusetts because they were invalid. 22 April 2021